Picture two people sharing a diagnosis, a string of failed medications, and even a doctor, who end up on very different roads to newer depression treatment. Often the difference is not medical at all. It is the card in their wallet.

This explainer walks through how the major types of coverage tend to shape that road, drawing on our summer poll of 443 adults spread over ten Midwest states. The goal is not to predict what your plan will do. Plans vary, and only yours can answer for itself. The goal is to help you know which questions apply to you.

Those poll figures are final; Pollfish has finished its validation.

Who the survey reached

We asked respondents what coverage they have, and allowed more than one answer. Commercial insurance led with 39 percent. Medicaid followed so closely, at 37 percent, that the two are nearly even. Medicare came to 23 percent, uninsured to 9 percent, and TRICARE to 5 percent, with 2 percent preferring not to say.

That spread matters because coverage is not a side detail for most people. Insurance made the two-item priority list of 85 percent of respondents; nothing else came close.

The treatment in question

Much of this conversation centers on Spravato, a nasal form of esketamine that the FDA approved for adults with depression unrelieved by earlier antidepressants. Certified clinics give it under supervision, observe patients for two hours or more afterward, and require a ride home. Brain Recovery Centers covers what esketamine costs under different kinds of coverage in more detail.

Ketamine offered in other ways, such as IV infusion clinics or at-home programs, sits outside that approval for depression. Insurance usually treats the two very differently, so it pays to know which one a clinic is offering.

If you have Medicaid

Medicaid is run by each state within federal rules, which means coverage decisions can differ from one state to the next. Many states contract with private managed care companies to administer benefits. In practice, that means the company named on your card, not the state agency, often decides whether a treatment is approved.

What tends to matter most:

• Whether esketamine is on your plan's list of covered drugs, and under which benefit.
• What the prior authorization requires, usually a record of antidepressants you have tried.
• Whether nearby certified sites accept your specific plan.
• Whether the plan offers rides to medical appointments, which can help with the no-driving rule.

If you have commercial insurance

Employer and individual plans are the most varied category. Two coworkers at different companies can have entirely different answers. Some plans place esketamine under the pharmacy benefit, others under the medical benefit, and some split costs between the two. Many hand mental health to a separate behavioral health company.

Questions worth asking:

• Which benefit covers the medication, and which covers the supervised visit?
• How much of my deductible remains this year?
• Is there a behavioral health vendor I should call instead of the main line?
• Which certified sites are in network for both parts of the bill?

If you have Medicare

About a quarter of our respondents reported Medicare. That stands out in a sample limited to adults under 65. Some younger people qualify for Medicare through disability, though our survey did not ask how anyone qualified. Medicare has several parts, and a drug-plus-observation visit may bill across more than one. Medicare Advantage plans, run by private insurers, add their own rules on top.

First pin down which Medicare you have, the original program or a private Advantage plan. Then ask how a clinic bills esketamine for Medicare patients, since that affects what you owe.

If you have TRICARE

TRICARE covers people in uniform, military retirees, and their families. It was our smallest coverage group, yet it matters to many households: about 7 percent of respondents, 29 of 443, were themselves veterans, service members, or first responders, and many more had one in the family. If TRICARE is your coverage, ask it the same core questions, and ask whether a referral from a primary care manager is required first.

If you have no coverage

For the uninsured, every route means paying directly, at least at first. It is still worth a few steps before deciding:

• Check whether you are now eligible for Medicaid in your state.
• Ask treatment sites for written self-pay pricing, including the evaluation.
• Ask about manufacturer or community assistance programs.
• Talk with a primary care provider or community health center about lower-cost depression care options overall.

What stays the same across every plan

Some parts of the road look alike no matter who pays.

Paperwork is common, and it is rarely a flat refusal. Just over half of our respondents would choose insurance with extra steps over simpler cash pay; the rest split fairly evenly between paying directly and not knowing.

Your doctor matters more than any ad. In our poll, a physician's recommendation would sway 74 percent, and 56 percent would visit a primary doctor first.

Distance matters too. Being close to home was named by 43 percent as a top-two factor in choosing a provider. Since every esketamine visit ends with a ride home from someone else, the nearest covered site is a practical question, not a small one.

What this is and is not

This is market research combined with general information about how coverage works. It is not medical advice, and it says nothing about what your particular plan covers. Esketamine's approval is narrow and it will not fit every patient; your clinician decides what fits.

If you are struggling right now, insurance can wait. Call or text 988, whatever your plan; the Suicide and Crisis Lifeline is free and staffed at any hour.

Methodology

Pollfish survey 395586438 took answers from consumer-panel members until its June 23, 2026 close; 443 completed it, each between 18 and 64, living in Wisconsin, Nebraska, Ohio, Indiana, Oklahoma, Illinois, Kansas, Iowa, Minnesota and Missouri. Coverage type and respondent background took multiple answers, so those totals can exceed 100. Every result here is final. The publisher commissioned and financed the research.